Perspectum Group, which provides a portfolio of medical imaging software, withdrew its plans for an initial public offering on Friday. It had filed to raise $75 million by offering 4.7 million shares at a price range of $15 to $17.
Perspectum's software products combine image formation, magnetic resonance (MR) image analysis, and artificial intelligence (AI) to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies, and cancer, and determine whether the patient is responding to therapy. Its product portfolio comprises cloud-based AI-driven software that utilizes medical images. Its flagship AI-driven product, LiverMultiScan, has been cleared by the FDA for non-invasive diagnosis and monitoring of liver disorders, which may include nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The company's SaaS platform products are currently enabled at approximately 350 locations worldwide.
The Oxfordshire, United Kingdom-based company was founded in 2012 and booked $9 million in revenue for the 12 months ended March 31, 2021. It had planned to list on the Nasdaq under the symbol SCAN. Citi, Barclays, Stifel, and Canaccord Genuity were set to be the joint bookrunners on the deal.
